SCHEMBL3051007

SCHEMBL3051007

O=C(CN1CCc2cc(Oc3ccc([N+](=O)[O-])cn3)ccc21)N1CCN(Cc2ccc3c(c2)OCO3)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.49
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
POLB P06746 2/20 0.48
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LMNA P02545 4/20 0.47
CYP3A4 P08684 2/20 0.47
ABCB11 O95342 1/20 0.47
CYP1A2 P05177 1/20 0.47
ADRA2A P08913 1/20 0.47
CYP2D6 P10635 1/20 0.47
CHRM1 P11229 1/20 0.47
TBXA2R P21731 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
CYP2C19 P33261 1/20 0.47
ADRA1A P35348 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3058663 0.88 MAPT (0.49) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL3050849 0.86 ALDH1A1 (0.51) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL3045821 0.81 LMNA (0.48) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL3057429 0.81 LMNA (0.47) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL3061112 0.81 MEN1 (0.48) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL3131386 0.79 ALDH1A1 (0.50) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL3147424 0.78 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MEN1KMT2APOLB
SCHEMBL3057442 0.78 LMNA (0.42) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL3142231 0.78 ALDH1A1 (0.49) ALDH1A1PKMSMN1; SMN2MEN1KMT2A
SCHEMBL3135139 0.78 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 ALDH1A1 741/4885PKM 3922/4885SMN1; SMN2 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.